Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD)

Expert Opinion on Biological Therapy

Volumn 9, Issue 5, 2009, Pages 649-657

  Geusens, Piet ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

CINODs; Cycloogenase inhibiting nitric oxide donators; Naproxcinod; Osteoarthritis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MISOPROSTOL; NAPROXCINOD; NAPROXEN; NITRIC OXIDE DONOR; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTHRITIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM EROSION; DUODEUM EROSION; EDEMA; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; INTESTINE MUCOSA PERMEABILITY; KNEE OSTEOARTHRITIS; LONG TERM CARE; NONHUMAN; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH EROSION; STOMACH INJURY; STROKE; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; NAPROXEN; NITRIC OXIDE DONORS; OSTEOARTHRITIS;

EID: 67649133149     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902926071     Document Type: Review

References (73)

1. Berenbaum F. New horizons and perspectives in the treatment of osteoarthritis. Arthritis Res Ther 2008;10(Suppl 2):S1
2. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981-1000
3. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus. Guidel Osteoarthritis Cartilage 2008;16:137-162 (Pubitemid 351222155)
4. Pencharz JN, Grigoriadis E, Jansz GF, Bombardier C. A critical appraisal of clinical practice guidelines for the treatment of lower-limb osteoarthritis. Arthritis Res 2002;4:36-44 (Pubitemid 34100488)
5. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American college of rheumatology subcommittee on osteoarthritis guidelines. Arthritis Rheum 2000;43:1905-1915
6. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-681 (Pubitemid 40559291)
7. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155 (Pubitemid 37500619)
8. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis 2009;68(1):8-17
9. The care and management of osteoarthritis in adults. National Institute for Health and Clinical Excellence, 2007. Available from: http://www.nice.org. uk/CG59 [Last accessed 2 April 2009]
10. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115(12):1634-1642 (Pubitemid 46648649)
11. Moskowitz RW, Abramson SB, Berenbaum F, et al. Coxibs and NSAIDs-is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis Cartilage 2007;15(8):849-856
12. Hochberg MC. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum 2002;32(3 Suppl 1):4-14 (Pubitemid 36055616)
13. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006;25(Suppl 1):S22-9 (Pubitemid 43933679)
14. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-1899 (Pubitemid 29272670)
15. Ofman JJ, MacLean CH, Straus WL, et al. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-812 (Pubitemid 34303877)
16. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti- inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-2099
17. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-8S (Pubitemid 28378015)
18. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28(5):527-532 (Pubitemid 17073216)
19. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-7568 (Pubitemid 29299702)
20. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-2050 (Pubitemid 24092039)
21. Fitzgerald GA. COX-2 and beyond. Nat Rev Drug Discov 2003:879
22. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528 (Pubitemid 30844348)
23. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102 (Pubitemid 40365350)
24. Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357:360-369 (Pubitemid 47124136)
25. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080 (Pubitemid 40365348)
26. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091 (Pubitemid 40365349)
27. Solomon DH. Selective cyclo-oxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005;52:1968-1978 (Pubitemid 40994317)
28. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255 (Pubitemid 30691365)
29. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-1781 (Pubitemid 44739003)
30. Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 2007;369:465-473 (Pubitemid 46217814)
31. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-684 (Pubitemid 39140623)
32. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-674
33. Geusens P, Lems W. Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis. Ther Clin Risk Manag 2008;4(2):337-344 (Pubitemid 351711993)
34. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-1642
35. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-1587
36. Zhang J, Ding EL. Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhytmia events. JAMA 2006;296:1619-1632
37. Mc Gettigan P, Henry D. Cardiovascular risk and inhibition of cyclo-oxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-1644
38. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase inhibitors and traditional non steroidal drugs increase the risk of athero-thrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-1305
39. Vonkeman HE, Brouwers JRBJ, van de Laar MAFJ. Understanding the NSAID related risk of vascular. events BMJ 2006;332:895-898
40. Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 2008;371(9608):270-273
41. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-1644 (Pubitemid 44511610)
42. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-1308
43. Wallace JL. Building a better aspirin: gaseous solutions to a century-old problem. Br J Pharmacol 2007;152:421-428 (Pubitemid 47585040)
44. Abramson SB. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 2008;10(Suppl 2):S2
45. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res Ther 2008;10(Suppl 2):S3
46. Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res Ther 2008;10(Suppl 2):S4
47. Schnitzer TJ. Introduction: from basic biology to therapeutic potential. Osteoarthritis Cartilage 2008;16(Suppl 2):S1
48. Feelisch M. The chemical biology of nitric oxide-an outsider's reflections about its role in osteoarthritis. Osteoarthritis Cartilage 2008;16(Suppl 2):S3-13
49. Abramson SB. Osteoarthritis and nitric oxide. Osteoarthritis Cartilage 2008;16(Suppl 2):S15-20
50. Raij L. Nitric oxide and cardiovascular and renal effects. Osteoarthritis Cartilage 2008;16(Suppl 2):S21-6
51. Brzozowski T, Konturek PC, Pajdo R, et al. Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins. J Physiol Pharmacol 2008;59(Suppl 2):89-102
52. Fiorucci S, Di Lorenzo A, Renga B, et al. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-α-methyl- 2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J Pharmacol Exp Ther 2004;311(3):1264-1271 (Pubitemid 39612736)
53. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88(11):4651-4655 (Pubitemid 21914599)
54. Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994;107(1):173-179
55. Wallace JL, Reuter B, Cicala C, et al. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 1994;257(3):249-255 (Pubitemid 24154581)
56. Brzozowska I, Targosz A, Sliwowski Z, et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol 2004;55(4):773-790 (Pubitemid 40053045)
57. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995;109(2):524-530
58. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci USA 2002;99(20):13243-13247
59. Brzozowski T, Konturek PC, Konturek SJ, et al. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs. Dig Liver Dis 2000;32(7):583-594
60. Berndt G, Grosser N, Hoogstraate J, Schroder H. A common pathway ofnitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci 2004;21:331-335 (Pubitemid 38156170)
61. Rossoni G, Manfredi B, del Soldato P, Berti F. The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J Pharmacol Exp Ther 2004;310:555-562 (Pubitemid 38988899)
62. Berndt G, Grosser N, Hoogstraate J, Schröder H. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci 2005;25(2-3):229-235 (Pubitemid 40725052)
63. Davies N, Roseth AG, Appleyard CB, et al. NO-naproxen vs. naproxen:ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 1997;11:69-79
64. Cuzzolin L, Conforti A, Adami A, et al. Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen. Pharmacol Res 1995;31:61-65
65. Muscará MN, McKnight W, Asfaha S, Wallace JL. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol 2000;129:681-686 (Pubitemid 30153851)
66. Muscará MN, Lovren F, McKnight W, et al. Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br J Pharmacol 2001;133:1314-1322 (Pubitemid 32783492)
67. Muscará MN, Lovren F, McKnight W, et al. Anti-hypertensive properties of a nitric oxide-releasing naproxen derivative in 2-kidney, 1-clip rats. Am J Physiol 2000;279:H528-35
68. Muscará MN, McKnight W, Del Soldato P, Wallace JL. Effect of a nitric oxide releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci 1998;62:PL235-40 (Pubitemid 28177436)
69. Hawkey CJ, Jones JI, Atherton CT, et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003;52:1537-1542 (Pubitemid 37363434)
70. Lohmander LS, McKeith D, Svensson O, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005;64:449-456 (Pubitemid 40283058)
71. Schnitzer TJ, Kivitz AJ, Lipetz RS, et al. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum 2005;53(6):827-837 (Pubitemid 41811122)
72. European Medicines Agency. Available from: http://www.emea.europa.eu/ pdfs/human/press/pr/PR-Lumiracoxib- 57930107en.pdf
73. Chan FK. Primer: managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006;3:563-573 (Pubitemid 44489589)